Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

21 views | Aug 22 2021

Ajai Chari et al. suggested that in addition to more frequent dose reductions, prompter and more aggressive supportive care might have contributed to the low discontinuation rate, longer duration therapy, and greater efficacy rates observed in the MSSM cohort. [Read the Full Post]

Neurocytological Advances in the Treatment of Glioblastoma Multiforme

17 views | Aug 22 2021

Brian Fiani et al. discussed the recent neurocytological treatment strategies for GMB and the results of the studies. [Read the Full Post]

The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia

68 views | Dec 07 2020

Delphine Verbeke et al. demonstrated that KPT-8602 enhanced the effects of dexamethasone to inhibit B-ALL and T-ALL cells via NR3C1- and E2F-mediated transcriptional complexes, allowing to achieve increased dexamethasone effects for patients. [Read the Full Post]

Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma

49 views | Dec 06 2020

Joel G Turner et al. found that inhibition of exportin 1 with selinexor synergistically sensitizeed human multiple myeloma to melphalan by inhibiting Fanconi anemia pathway-mediated DNA repair. [Read the Full Post]

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection

82 views | Jul 30 2020

Panagiotis Malandrakis et al. showed that selinexor was a new anti-myeloma drug that seemed to be effective in patients who had no other therapeutic options, including patients who had received novel cellular therapies such as CAR-T cells. [Read the Full Post]

Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition

91 views | Jul 30 2020

Isabel Jiménez et al. highlighted the pathogenic role of the innate immune microenvironment in PCNSL and provided pre-clinical evidence for the development of selinexor and ibrutinib as a new promising therapeutic option with cytotoxic and immunomodulatory potential. [Read the Full Post]

The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity Against Acute Lymphoblastic Leukemia

150 views | Mar 01 2020

Thomas Vercruysse et al. showed that KPT-8602 is highly specific for XPO1 inhibition and demonstrates potent anti-leukemic activity supporting clinical application of the second-generation SINE compound for the treatment of ALL. [Read the Full Post]

Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis

164 views | Feb 28 2020

Dongqing Yan et al. implicated NCT as a potential therapeutic target in myelofibrosis and provide a rationale for clinical evaluation in ruxolitinib-exposed patients with myelofibrosis. [Read the Full Post]

KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib

205 views | Oct 13 2019

Nie D et al. indicated that KPT-330 showed anti-leukemic activity and sensitized CML to IM in CRM1-dependent manner in vitro and in vivo. KPT-330 represents an alternative therapy for IM-refractory CML, warranting further investigation of CRM1 as therapeutic target. [Read the Full Post]

Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis

282 views | Oct 10 2019

Machlus KR et al. revealed (1) the mechanism of selinexor-induced thrombocytopenia, (2) an effective way to reverse the dose-limiting thrombocytopenia, and (3) a novel role for XPO1 in megakaryopoiesis. The improved selinexor dosing regimen described herein is crucial to help reduce thrombocytopenia in selinexor patients, allowing them to continue their course of chemotherapy and have the best chance of survival. [Read the Full Post]